drugset / Trial / NCT03759353

Lactoferrin Versus Ferrous Sulfate in Iron-deficiency During Pregnancy

NCT03759353

Phase 2 Completed 98 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

The main drawbacks with oral iron are side-effects, poor compliance, and limited absorption from the gut. It has become very apparent gastrointestinal intolerance with oral iron therapy is dose related and common (up to 20% of patients), and this frequently leads to poor compliance. Lactoferrin (formerly known as lactotransferrin) is a glycoprotein, and a member of a transferrin family, thus belonging to those proteins capable of binding and transferring iron. It represents an attractive and promising alternative to ferrous sulphate oral administration as pregnant women receiving lactoferrin did not experience any adverse effects. This study aims to compare between lactoferrin and ferrous sulphate for therapy of iron deficiency in pregnant women.

Timeline

Start
2018-01-15
Primary completion
2018-10-30
Completion
2018-11-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ferrous Sulfate Diagnostic / imaging agent 200 mg Oral
Comparator Lactoferrin Protein / enzyme biologic 100 mg Oral